Eli Lilly throws SCOTUS hail mary in Cialis patent infringement fight

Looking at a future swarming with generic challengers, Eli Lilly’s Cialis is already feeling the burden on its global sales. Now, after Cialis’ $20 million patent infringement loss in benign prostatic hyperplasia (BPH), the drugmaker is taking the fight to the Supreme Court.